Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 13/20 | 0.75 |
| ▸ | CTSB | P07858 | 7/20 | 0.75 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7693912 | 0.91 | CAPN1 (0.73) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7696167 | 0.89 | CAPN1 (0.57) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7698259 | 0.87 | CAPN1 (0.61) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7696527 | 0.86 | CAPN1 (0.65) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7695427 | 0.85 | CAPN1 (0.56) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7692161 | 0.85 | CAPN1 (0.70) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7691158 | 0.84 | CAPN1 (0.54) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL7696093 | 0.84 | CAPN1 (0.54) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1930492 | 0.84 | CAPN1 (0.86) | CAPN1CTSBCTSSCTSKCTSL | |
| SCHEMBL1930489 | 0.84 | CAPN1 (0.86) | CAPN1CTSBCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436925-B1 | BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |